PSTX Penghasilan resik perusahaan poseida.com

Poseida Therapeutics (PSTX) relies on competent management and a transparent alliance with Roche to minimize risks. This chart in the GURU.Markets terminal illustrates the company's revenue surplus, where the value has stabilized at -0.06. The brand's impeccable status in oncology guarantees market confidence, while the platform's versatility ensures high scalability of products for combating various diseases.

PSTX Poseida Therapeutics, Inc.: Penghasilan resik ing interval 04.07.2022 - 18.01.2025

Rincian metrik keuangan lan pasar Poseida Therapeutics, Inc. (PSTX)

- rega saham lan konsensus proyeksi valuasi:

Bagan rega Poseida Corp|PSTX - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Poseida Corp|PSTX - Nilai Perusahaan

- data ekuitas miturut neraca:

Nilai Buku Siji Saham Poseida Therapeutics|PSTX - Aset Bersih Perusahaan|Koefisien Nilai Pasar marang Nilai Buku poseida.com|PSTX - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi Poseida Therapeutics|PSTX - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Poseida Therapeutics Inc|PSTX - Gunggung utang perusahaan|Utang-utang marang nilai buku Poseida Corp|PSTX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Poseida Therapeutics|Likuiditas cepet poseida.com

- data bathi bisnis lan rasio investasi:

PSTX - Penghasilan resik

Pambiji fundamental:PSTX Poseida Corp

This indicator determines the issuer's investment stability by measuring the gap between actual cash flows and market capitalization to identify undervalued assets. By analyzing the quarterly earnings of Poseida Therapeutics (PSTX), an investor can gauge the monetization efficiency of CAR-T therapy, where high R&D costs and the implementation of the non-viral piggyBac system directly impact final profitability and the long-term potential of Poseida Therapeutics.

Pesaing utama